Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all – in - one diabetes management system, announces the findings of a new in vitro study published in European Endocrinology. The study demonstrates that the Cellnovo Diabetes Management System is more accurate and consistent than the Insulet OmniPod® System (“OmniPod”), a tubeless insulin pump.